Literature DB >> 32314704

Ivermectin and COVID-19: Keeping Rigor in Times of Urgency.

Carlos Chaccour1,2,3, Felix Hammann4, Santiago Ramón-García5,6, N Regina Rabinovich7,1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32314704      PMCID： PMC7253113          DOI： 10.4269/ajtmh.20-0271

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN： 0002-9637            Impact factor:   2.345


× No keyword cloud information.
  22 in total

1.  Safety, tolerability, and pharmacokinetics of escalating high doses of ivermectin in healthy adult subjects.

Authors:  Cynthia A Guzzo; Christine I Furtek; Arturo G Porras; Cong Chen; Robert Tipping; Coleen M Clineschmidt; David G Sciberras; John Y K Hsieh; Kenneth C Lasseter
Journal:  J Clin Pharmacol       Date:  2002-10       Impact factor: 3.126

2.  Ivermectin is a potent inhibitor of flavivirus replication specifically targeting NS3 helicase activity: new prospects for an old drug.

Authors:  Eloise Mastrangelo; Margherita Pezzullo; Tine De Burghgraeve; Suzanne Kaptein; Boris Pastorino; Kai Dallmeier; Xavier de Lamballerie; Johan Neyts; Alicia M Hanson; David N Frick; Martino Bolognesi; Mario Milani
Journal:  J Antimicrob Chemother       Date:  2012-04-25       Impact factor: 5.790

3.  HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833.

Authors:  J Drewe; H Gutmann; G Fricker; M Török; C Beglinger; J Huwyler
Journal:  Biochem Pharmacol       Date:  1999-05-15       Impact factor: 5.858

4.  Treating COVID-19-Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics.

Authors:  Andre C Kalil
Journal:  JAMA       Date:  2020-03-24       Impact factor: 56.272

5.  A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection.

Authors:  Nicholas J Barrows; Rafael K Campos; Steven T Powell; K Reddisiva Prasanth; Geraldine Schott-Lerner; Ruben Soto-Acosta; Gaddiel Galarza-Muñoz; Erica L McGrath; Rheanna Urrabaz-Garza; Junling Gao; Ping Wu; Ramkumar Menon; George Saade; Ildefonso Fernandez-Salas; Shannan L Rossi; Nikos Vasilakis; Andrew Routh; Shelton S Bradrick; Mariano A Garcia-Blanco
Journal:  Cell Host Microbe       Date:  2016-07-28       Impact factor: 21.023

6.  Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin.

Authors:  M Y F Tay; J E Fraser; W K K Chan; N J Moreland; A P Rathore; C Wang; S G Vasudevan; D A Jans
Journal:  Antiviral Res       Date:  2013-06-14       Impact factor: 5.970

7.  Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus.

Authors:  Kylie M Wagstaff; Haran Sivakumaran; Steven M Heaton; David Harrich; David A Jans
Journal:  Biochem J       Date:  2012-05-01       Impact factor: 3.857

8.  Selamectin Is the Avermectin with the Best Potential for Buruli Ulcer Treatment.

Authors:  Nicole Scherr; Gerd Pluschke; Charles J Thompson; Santiago Ramón-García
Journal:  PLoS Negl Trop Dis       Date:  2015-08-13

9.  Relative neurotoxicity of ivermectin and moxidectin in Mdr1ab (-/-) mice and effects on mammalian GABA(A) channel activity.

Authors:  Cécile Ménez; Jean-François Sutra; Roger Prichard; Anne Lespine
Journal:  PLoS Negl Trop Dis       Date:  2012-11-01

10.  A Roadmap for the Development of Ivermectin as a Complementary Malaria Vector Control Tool.

Authors:  Peter Billingsley; Fred Binka; Carlos Chaccour; Brian Foy; Silvia Gold; Matiana Gonzalez-Silva; Julie Jacobson; George Jagoe; Caroline Jones; Patrick Kachur; Kevin Kobylinski; Anna Last; James V Lavery; David Mabey; David Mboera; Charles Mbogo; Ana Mendez-Lopez; N. Regina Rabinovich; Sarah Rees; Frank Richards; Cassidy Rist; Jessica Rockwood; Paula Ruiz-Castillo; Jetsumon Sattabongkot; Francisco Saute; Hannah Slater; Andrew Steer; Kang Xia; Rose Zullinger
Journal:  Am J Trop Med Hyg       Date:  2020-02       Impact factor: 2.345
View more
  42 in total

Review 1.  Current status of therapeutic alternatives for COVID-19: A narrative review.

Authors:  Abdullah Tarık Aslan; Murat Akova
Journal:  Infez Med       Date:  2021-09-10

2.  Potential therapeutic effects of Ivermectin in COVID-19.

Authors:  Nastaran Barati; Seyedmousa Motavallihaghi; Banafsheh Nikfar; Shahla Chaichian; Amir Abbas Momtazi-Borojeni
Journal:  Exp Biol Med (Maywood)       Date:  2022-06-10

Review 3.  Ivermectin: An Anthelmintic, an Insecticide, and Much More.

Authors:  Richard J Martin; Alan P Robertson; Shivani Choudhary
Journal:  Trends Parasitol       Date:  2020-11-11

4.  In silico studies of selected multi-drug targeting against 3CLpro and nsp12 RNA-dependent RNA-polymerase proteins of SARS-CoV-2 and SARS-CoV.

Authors:  Inemesit A Udofia; Kofoworola O Gbayo; Oluwakemi A Oloba-Whenu; Taofeek B Ogunbayo; Chukwuemeka Isanbor
Journal:  Netw Model Anal Health Inform Bioinform       Date:  2021-03-25

5.  Identification and Development of Therapeutics for COVID-19.

Authors:  Halie M Rando; Nils Wellhausen; Soumita Ghosh; Alexandra J Lee; Anna Ada Dattoli; Fengling Hu; James Brian Byrd; Diane N Rafizadeh; Ronan Lordan; Yanjun Qi; Yuchen Sun; Christian Brueffer; Jeffrey M Field; Marouen Ben Guebila; Nafisa M Jadavji; Ashwin N Skelly; Bharath Ramsundar; Jinhui Wang; Rishi Raj Goel; YoSon Park; Simina M Boca; Anthony Gitter; Casey S Greene
Journal:  mSystems       Date:  2021-11-02       Impact factor: 6.496

6.  A Large Impact of Obesity on the Disposition of Ivermectin, Moxidectin and Eprinomectin in a Canine Model: Relevance for COVID-19 Patients.

Authors:  Alain Bousquet-Mélou; Anne Lespine; Jean-François Sutra; Isabelle Bargues; Pierre-Louis Toutain
Journal:  Front Pharmacol       Date:  2021-05-20       Impact factor: 5.810

Review 7.  Fundamental and Advanced Therapies, Vaccine Development against SARS-CoV-2.

Authors:  Nikola Hudakova; Simona Hricikova; Amod Kulkarni; Mangesh Bhide; Eva Kontsekova; Dasa Cizkova
Journal:  Pathogens       Date:  2021-05-21

8.  Safety of inhaled ivermectin as a repurposed direct drug for treatment of COVID-19: A preclinical tolerance study.

Authors:  Suzan M Mansour; Rehab N Shamma; Kawkab A Ahmed; Nirmeen A Sabry; Gamal Esmat; Azza A Mahmoud; Amr Maged
Journal:  Int Immunopharmacol       Date:  2021-07-23       Impact factor: 4.932

9.  Clinical study evaluating the efficacy of ivermectin in COVID-19 treatment: A randomized controlled study.

Authors:  Sherief Abd-Elsalam; Rasha A Noor; Rehab Badawi; Mai Khalaf; Eslam S Esmail; Shaimaa Soliman; Mohamed S Abd El Ghafar; Mohamed Elbahnasawy; Ehab F Moustafa; Sahar M Hassany; Mohammed A Medhat; Haidi Karam-Allah Ramadan; Maii A S Eldeen; Mohamed Alboraie; Ahmed Cordie; Gamal Esmat
Journal:  J Med Virol       Date:  2021-06-07       Impact factor: 20.693

10.  Antiviral effect of high-dose ivermectin in adults with COVID-19: A proof-of-concept randomized trial.

Authors:  Alejandro Krolewiecki; Adrián Lifschitz; Matías Moragas; Marina Travacio; Ricardo Valentini; Daniel F Alonso; Rubén Solari; Marcelo A Tinelli; Rubén O Cimino; Luis Álvarez; Pedro E Fleitas; Laura Ceballos; Marcelo Golemba; Florencia Fernández; Diego Fernández de Oliveira; German Astudillo; Inés Baeck; Javier Farina; Georgina A Cardama; Andrea Mangano; Eduardo Spitzer; Silvia Gold; Carlos Lanusse
Journal:  EClinicalMedicine       Date:  2021-06-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.